Additional file 1 of Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

Additional file 1: Table S1. ICI outcomes assigned to each study sample. Table S2. Detailed lung cancer cohort patient description. Table S3. Classifying FSPs in full cohort all-response model. Table S4. Classifying FSPs in response model without stable disease. Table S5. Classifying FSPs in monotherapy response model. Table S6. Classifying FSPs in NSCLC response model. Table S7. Classifying FSPs in adverse event model. Table S8. GO analysis of source genes for the classifying FSPs comprising the response without SD and monotherapy response models. Table S9. Expression levels* of source genes for irAE-classifying FSPs.